

ASX Announcement

3 September 2026

BCAL Diagnostics seeks board change at Genetic Signatures

Highlights

- **BCAL Diagnostics has given a s249D notice to Genetic Signatures seeking board change**

BCAL Diagnostics Limited (ASX: BDX), as the holder of more than 5% of the shares in Genetic Signatures Limited (ASX: GSS), has given a notice under section 249D of the Corporations Act 2001(Cth) to GSS requesting that GSS convene a general meeting to consider resolutions to remove Mr Michael Aicher from office as a director and to appoint to the board Ms Susan Forrester and Mr John Melki, a former CEO and director of GSS, as confirmed by GSS in its announcement to ASX today.

BCAL included in its substantial holder notice filed with ASX on 26 August 2026 informing the market that it had increased its shareholding in GSS from 23,173,644 shares (10.2%) by acquiring, in an off market transaction, a second parcel of 18,750,000 shares (Second Parcel) to 41,923,644 shares (18.46%) that the vendor remained the registered holder of the Second Parcel, as is always the case, pending registration of the transfer by the share registry of GSS. The transfer of the Second Parcel was registered on 2 September 2026. GSS appears to have reviewed an outdated version of its share register from 31 August 2026.

BCAL engaged corporate adviser and investment bank, Kidder Williams, to assist it with the acquisition of its interest in GSS. BCAL understands that Kidder Williams used an associated entity to facilitate the acquisition in the proper performance of the functions attaching to its professional capacity in performing that mandate. Kidder Williams is not an associate of BCAL.

Authorised by the Board for release to the ASX.

ENDS

For further information:

Jayne Shaw

Non-Executive Chair

jshaw@bcaldiagnostics.com

Anne-Louise Arnett

Chief Executive Officer

aarnett@bcaldiagnostics.com